Monitor for partnership announcements over the coming months as Pullan Consulting initiates the partnering process. A licensing deal with upfront and milestone payments could be transformative given the $7M market cap. The Phase 2 trial design is ready but has not yet started enrollment — watch for trial initiation as a catalyst.
Price Chart
Executive Summary
Immuron engaged Pullan Consulting to secure a strategic partner for its IMM-529 program targeting C. difficile infection. The company has FDA IND approval, completed drug product manufacturing, and a Phase 2 trial design ready to enroll up to 60 subjects, with a projected base-case yearly revenue of US$400M if successful.
Key Facts
- Engaged Pullan Consulting, a life sciences advisory firm with a track record of 5-12 partnering transactions annually over 20 years
- FDA approval for IMM-529 IND (IND 32095) for Phase 2 clinical trial in C. difficile infection
- Phase 2 trial design: randomized, double-blind, placebo-controlled, up to 60 subjects, 2:1 randomization
- Drug product manufactured and released for clinical trial supply
- Base case yearly revenue for IMM-529 projected at US$400M if positioned at first recurrence
- Historical CDI deal comparables: upfront payments $1M-$50M, milestones $25M-$570M, royalties mid-to-high single digit
- Market cap ~$7M, making a successful partnership potentially transformational
Financial Impact
Base case yearly revenue projected at US$400M for IMM-529 if positioned at first recurrence; historical CDI deal comparables show upfront payments $1M-$50M, milestones $25M-$570M, and mid-to-high single digit royalties
Risk Factors
- No guarantee a partnership will be secured on favorable terms or at all
- Phase 2 trial has not yet commenced; clinical failure risk remains high for early-stage assets
- Competition from existing CDI treatments including Bezlotoxumab and standard-of-care antibiotics
- Projected $400M revenue is a base case estimate and depends on clinical efficacy and market positioning
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3322259 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9200 (−1.08%) |
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9200 (−3.06%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9200 (−6.32%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9200 (−11.54%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9200 (−26.69%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9200 (−48.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers